A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer.
Gefitinib; endometrial cancer; epidermal growth factor receptor (EGFR); soluble EGFR; estrogen receptor; progesterone receptor
Copyright © Kimberly K. Leslie, Michael W. Sill, Edgar Fischer, Kathleen M. Darcy, Robet S. Mannel, Krishnansu S. Tewari, Parviz Hanjan, Jason A. Wilken, Andre T. Baron, Andrew K. Godwin, Russell J. Schilder, Meenakshi Singh, Nita J. Maihle, 2013.
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.